Mirum Pharmaceuticals' Volixibat Meets Primary Endpoint in Phase 2b PSC Study, Plans H2 2026 NDA Submission
MIRM has more than doubled off its 52-week low of $40.001.
Summary
Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in primary sclerosing cholangitis (PSC), demonstrating significant pruritus improvement and setting a path for an H2 2026 NDA submission.
Key Events · Product Development and Regulatory · MIRM
-
Volixibat Achieves Primary Endpoint in PSC Study
The VISTAS Phase 2b study for volixibat in primary sclerosing cholangitis (PSC) met its primary endpoint, showing a robust 2.72 point improvement in pruritus and a placebo-adjusted difference of 1.64 points (p<0.0001).
-
Clear Regulatory Path Ahead
A pre-New Drug Application (NDA) meeting for volixibat in PSC is scheduled with the FDA in summer 2026, with a planned NDA submission in the second half of 2026.
-
Safety Profile Consistent with IBAT Inhibition
Volixibat's safety profile was generally consistent with known IBAT inhibition effects, primarily characterized by gastrointestinal adverse events and elevations in liver laboratory parameters.
-
PBC Data Expected Q1 2027
Topline data from the VANTAGE Phase 2b study of volixibat in primary biliary cholangitis (PBC) is now expected in the first quarter of 2027.
Analysis · MIRM · Life Sciences
Mirum Pharmaceuticals reported highly positive Phase 2b results for volixibat in primary sclerosing cholangitis (PSC), a significant clinical milestone. The drug demonstrated a statistically significant improvement in pruritus, a key symptom, with a robust placebo-adjusted difference. This success, coupled with a scheduled pre-NDA meeting and a planned NDA submission in the second half of 2026, indicates a clear and accelerated path towards potential market approval. While topline data for the PBC study was pushed to Q1 2027, the strong PSC results for volixibat are a major positive catalyst, building on the company's recent positive clinical news for brelovitug.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRM was trading at $100.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $40.00 to $109.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.